The Age
·general
·1 hour ago
Everlab prioritizes safety over profits, rejects peptide offerings amid inquiries
Everlab, a Melbourne health start-up, rejected peptide offerings despite daily inquiries, prioritizing safety over profits. CEO Marc Hermann emphasized the need for caution due to limited studies on the compounds. The company, now valued at nearly $500 million after a $65 million funding round, has expanded its member base to over 20,000, targeting broader Australian audiences.
Summary by Glance · The Age
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI